Search - tctmd.com

Displaying 1 - 20 of 35

Sort: Relevancy | Date

News Features

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Michael O'Riordan

December 09, 2019

News Conference News AHA 2019

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Yael L. Maxwell

November 21, 2019

News Daily News

Grief and CVD: Simple Regimen May Lower Risk

L.A. McKeown

November 19, 2019

News Daily News

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

Michael O'Riordan

October 17, 2019

News Conference News TCT 2019

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Todd Neale

October 03, 2019

Off Script: A (Not So) Brief History of Aspirin’s Rise and Fall

News Opinion Off Script TCT 2019

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Kwan S. Lee

September 29, 2019

Presentation TCT 2019

Is Troponin Elevation After Noncardiac Surgery an Indication to Antithrombotic Treatment?

Presenter: Francesco Franchi

September 27, 2019

Presentation TCT 2019

Reversal Strategies for Warfarin and NOACs: The Essentials

Presenter: Teresa Carman

September 27, 2019

Presentation TCT 2019

When and How to Switch to OAC Alone After PCI?

Presenter: Manesh Patel

September 27, 2019

Presentation TCT 2019

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

Presenter: Dominick Angiolillo

September 27, 2019

Presentation TCT 2019

PCI in Patients Requiring OAC: Which OAC and in Whom?

Presenter: Davide Capodanno

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presentation TCT 2019

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Presenter: Robert Byrne

September 27, 2019

Debate: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients - Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presentation TCT 2019

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

Presenter: C. Michael Gibson

September 27, 2019

News TCT 2019

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

Shelley Wood

September 26, 2019

News Conference News TCT 2019

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Todd Neale

September 26, 2019

News Conference News TCT 2019

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

L.A. McKeown

September 26, 2019

Presentation TCT 2019

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

Presenter: Robert Welsh

September 26, 2019

News Conference News TCT 2019

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Yael L. Maxwell

September 26, 2019

Presentation TCT 2019

Antithrombotic Therapy in PCI Patients With Atrial Fibrillation

Presenter: Marco Valgimigli

September 25, 2019

News Daily News

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Caitlin E. Cox

September 20, 2019

Advertisement

Year in Review: ISCHEMIA Tops Coronary News in 2019 but Other Trials Shine, Too

Apabetalone Falls Short in Diabetic ACS Patients With Low HDL: BETonMACE

Grief and CVD: Simple Regimen May Lower Risk

DAPT Cuts Saphenous Vein Graft Failure After CABG: Meta-analysis

TICAKOREA: Ticagrelor Ups Bleeding Over Clopidogrel in Korean ACS Patients

Off Script: The TWILIGHT of Aspirin? A Brief History of ASA’s Rise and Fall

Is Troponin Elevation After Noncardiac Surgery an Indication to Antithrombotic Treatment?

Reversal Strategies for Warfarin and NOACs: The Essentials

When and How to Switch to OAC Alone After PCI?

AFib Patients at High Ischemic Risk Post-PCI: Role of Triple Therapy or Potent P2Y12 Inhibition?

PCI in Patients Requiring OAC: Which OAC and in Whom?

Con: Beware of Ischemic Complications — Not Ready to Drop DAPT Yet!

Pro: Dual Therapy (OAC+SAPT) Should Be the Default Therapy at Discharge in Most Patients

TCT 2019 Day One: TWILIGHT and Onyx ONE Kick Things Off

AUGUSTUS: Apixaban-Based Dual Therapy Best Across Major Subgroups

Onyx ONE: Shorter DAPT Plus ZES Noninferior to Polymer-Free Stent in High-Bleeding-Risk Patients

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

TWILIGHT: Ticagrelor Monotherapy Lowers Bleeding Without Increasing Ischemic Events

Antithrombotic Therapy in PCI Patients With Atrial Fibrillation

Major Bleeding Mostly Early, Not Severe With Rivaroxaban Plus Aspirin in COMPASS

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content